2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Not applicable, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow BRCA 1 Gene Mutation: new trials by email Literature Review of BRCA 1 Gene Mutation trials Research Report on BRCA 1 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants Galleri Multi-Cancer Early Detection (MCED) Blood Test - Ovarian Neoplasms, BRCA 1 Gene Mutation | Not applicable | Not yet recruiting | Weill Medical College of Cornell University | 70 | 2026-10-01 | 2026-10-16 |
| A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) Endoscopic nipple sparing mastectomy, HandX endoscopic instrument - Breast Cancer, BRCA 1 Gene Mutation | Not applicable | Recruiting | Vasileios Kalles | 15 | 2025-09-09 | 2025-12-18 |
| Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer Neoadjuvant Chemotherapy (NACT) - Breast Cancer (Early Breast Cancer), BRCA 1 Gene Mutation | Not applicable | Active not recruiting | N.N. Petrov National Medical Research Center of Oncology | 30 | 2022-09-27 | 2026-09-15 |
| A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients SC10914 - Breast Cancer Metastatic, BRCA 1 Gene Mutation | Phase 2 | Unknown | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 78 | 2020-08-12 | 2020-09-21 |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Olaparib, Physician's choice chemotherapy - Breast Cancer Metastatic, BRCA 1 Gene Mutation | Phase 3 | Completed | AstraZeneca | 302 | 2014-03-27 | 2026-02-13 |
| A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) talazoparib - Breast Neoplasms, BRCA 1 Gene Mutation | Phase 2 | Terminated | Pfizer | 84 | 2013-12-13 | 2019-10-14 |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) talazoparib, Physician's-Choice - Breast Neoplasms, BRCA 1 Gene Mutation | Phase 3 | Completed | Pfizer | 431 | 2013-10-14 | 2022-01-20 |
Breast Neoplasms (5) · Breast Cancer, Familial (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Fanconi Anemia, Complementation Group D1 (1) · Hereditary Breast and Ovarian Cancer Syndrome (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1)
talazoparib (2) · Hematologic Tests (1) · Neoadjuvant Therapy (1) · olaparib (1)
Pfizer (2) · AstraZeneca (1) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Vasileios Kalles (1) · Weill Medical College of Cornell University (1)
United States (4) · France (3) · Russia (3) · Spain (3) · United Kingdom (3) · China (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Taiwan (2) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1)
Mark Robson, MD (1) · Melissa K Frey, MD, MS (1) · Vasileios Kalles, MD, MSc, PhD, FEBS (1)
PMID 28578601, PMID 30110579, PMID 30124753, PMID 30563931, PMID 35091441, PMID 37803017